Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous dendritic cell melanoma vaccine with or without low-dose interleukin-2
ACTRN12608000355370Phase 2Completed
- Sponsor
- National Health and Medical Research Council
- Start
- Feb 2003
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing Autologous dendritic cell vaccine alone with Autologous dendritic cell vaccine plus interleukin-2 (2 arms). Primary endpoint: Immune and clinical response with matured versus non-matured dendritic cells. Started Feb 2003; status: completed.
02
Drugs
autologous dendritic cell vaccinealdesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12608000355370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000355370.